October 10, 2019
1 min read
Save
TCR-engineered T Cells in Solid Tumors (ACTengine)
Issue: October/November 2019
Phase 1 study evaluating the safety and tolerability of genetically modified autologous T cells expressing a T-cell receptor recognizing a cancer/germline antigen in patients with relapsed and/or refractory solid tumors (ACTengine IMA203-101)
